Clinical Scorecard: Musings from The Power List: Ansgar Korf

At a Glance

Key Highlights

• The interviewee says the MZmine team develops computational methods and open infrastructure to address data-processing bottlenecks in untargeted mass spectrometry.
• FAIR-MS is described as applying MZmine processing capabilities to make mass spectrometry data findable and reusable at the scale needed for machine learning.
• Untargeted datasets can be revisited years later to address questions that were not anticipated when data were acquired.
• The interviewee says targeted methods remain essential wherever a validated answer is required.
• The interviewee says study design, sampling, sample preparation, acquisition, and processing each constrain what the other workflow stages can achieve.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Not applicable; the article concerns analytical science and mass spectrometry research, not patient care.

No treatments or prescribing information are discussed.

Clinical Best Practices

• Consider study design, sampling, sample preparation, acquisition, and processing as interdependent parts of the analytical workflow.
• Address systematic sources of error across the workflow; the source cautions that scale alone does not remedy systematic error.
• Make mass spectrometry data comparable and reusable to support large-scale machine-learning applications.

Related Resources & Content